Skip to main content

Table 3 Characteristics of patients with moderate to severe airflow limitation

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

  Patients with moderate to severe AFL (n = 61)
LAMA/LABA LAMA p value* No-BD p value**
n = 32 n = 22 n = 7
Age 72. 2 ± 6.7 70.8 ± 6.6 0.236 69.9 ± 5.6 0.406
Sex    0.804   0.929
 Male 27 (84.4) 18 (81.8)   6 (85.7)  
 Female 5 (15.6) 4 (18.2)   1 (14.3)  
Smoking status    0.412   0.262
 Current smoker 11 (34.4) 10 (45.5)   4 (57.1)  
 Ex-smoker 21 (65.6) 12 (54.5)   3 (42.9)  
Severity of AFL    0.344   0.399
 Moderate 29 (90.6) 18 (81.8)   7 (100)  
 Severe 3 (9.4) 4 (18.2)   0  
Comorbidities      
 Cardiovascular disease 16 (50.0) 13 (59.1) 0.510 6 (85.7) 0.084
 Diabetes mellitus 6 (18.8) 6 (27.3) 0.459 3 (42.9) 0.170
Surgical procedure    0.098   0.887
 Lobectomy 26 (81.3) 22 (100)   6 (85.7)  
 Segmentectomy 1 (3.1) 0   0  
 Partial resection 5 (15.6) 0   1 (14.3)  
Pathologic staging    0.016   0.148
 I 26 (81.3) 11 (50.0)   4 (57.1)  
 II 2 (6.3) 8 (36.4)   0  
 III 4 (12,5) 3 (13.6)   3 (42.9)  
Adjuvant chemotherapy 4 (12.5) 5 (22.7) 0.322 2 (28.6) 0.286
Recurrence (present) 4 (12.5) 10 (45.5) 0.006 4 (57.1) 0.008
 Treatment for recurrence      
 Anticancer drug 2 7   3  
 Molecular targeted drug 0 1   1  
 None 2 2   0  
  1. Data are presented as n (%) or as mean ± SD
  2. COPD chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; AFL airflow limitation